药效动力学模型优化舒巴坦的剂量方案。
Pharmacodynamics modeling to optimize dosage regimens of sulbactam.
机构信息
Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand.
出版信息
Antimicrob Agents Chemother. 2013 Jul;57(7):3441-4. doi: 10.1128/AAC.00342-13. Epub 2013 May 6.
Abstract
The aim of this study was to reveal population pharmacokinetics and assess the efficacies of various dosage regimens of sulbactam in terms of the probability of target attainment with this agent over a range of MICs. Monte Carlo simulations were performed to determine the probability of attaining specific pharmacodynamic targets. The results indicated that a regimen consisting of a 4-h infusion of 3 g of sulbactam every 8 h would be an alternative treatment option for less-susceptible pathogens.
摘要
本研究旨在揭示人群药代动力学，并评估不同剂量方案的舒巴坦在一系列 MIC 值范围内针对该药物达到特定药效学目标的概率。通过蒙特卡罗模拟来确定达到特定药效学目标的概率。结果表明，每 8 小时输注 3 g 舒巴坦 4 小时的方案可能是针对低敏感性病原体的替代治疗选择。
相似文献
1
Pharmacodynamics modeling to optimize dosage regimens of sulbactam.药效动力学模型优化舒巴坦的剂量方案。
Antimicrob Agents Chemother. 2013 Jul;57(7):3441-4. doi: 10.1128/AAC.00342-13. Epub 2013 May 6.
2
Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.肾功能受损患者中舒巴坦的群体药代动力学-药效学目标达成分析：鲍曼不动杆菌感染的给药考量
J Infect Chemother. 2015 Apr;21(4):284-9. doi: 10.1016/j.jiac.2014.12.005. Epub 2014 Dec 26.
3
Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.群体药代动力学和药效学建模以优化鲍曼不动杆菌引起的严重脓毒症重症患者的舒巴坦给药方案
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7236-7244. doi: 10.1128/AAC.01669-16. Print 2016 Dec.
4
Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii.群体药代动力学和蒙特卡罗模拟研究用于优化鲍曼不动杆菌呼吸机相关性肺炎患者的舒巴坦剂量方案。
Eur J Pharm Sci. 2019 Aug 1;136:104940. doi: 10.1016/j.ejps.2019.05.018. Epub 2019 May 25.
5
Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations.氨苄西林-舒巴坦治疗鲍曼不动杆菌感染：当前药敏折点和推荐剂量的药代动力学/药效学评价。
J Antimicrob Chemother. 2024 Sep 3;79(9):2227-2236. doi: 10.1093/jac/dkae218.
6
Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Using Checkerboard Information.舒巴坦/美罗培南/多黏菌素 B 联合用药对极度耐药的药效学影响。采用棋盘信息法。
Microb Drug Resist. 2019 Nov;25(9):1266-1274. doi: 10.1089/mdr.2018.0283. Epub 2019 Jun 19.
7
In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.氨苄西林/舒巴坦、多利培南和替加环素单独及联合用于模拟人体暴露时对多重耐药鲍曼不动杆菌的体外药效学研究。
J Antimicrob Chemother. 2013 Oct;68(10):2296-304. doi: 10.1093/jac/dkt197. Epub 2013 May 24.
8
Pharmacokinetic and pharmacodynamic profiling of four antimicrobials against Acinetobacter baumannii infection.四种抗菌药物对鲍曼不动杆菌感染的药代动力学和药效学特征分析。
Microb Pathog. 2020 Jan;138:103809. doi: 10.1016/j.micpath.2019.103809. Epub 2019 Oct 18.
9
Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.体外和小鼠大腿及肺部感染模型中评估舒巴坦对鲍曼不动杆菌的药代动力学/药效学。
Int J Antimicrob Agents. 2014 Jun;43(6):547-52. doi: 10.1016/j.ijantimicag.2014.02.012. Epub 2014 Mar 30.
10
High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.高剂量氨苄西林-舒巴坦组合在中空纤维感染模型中对抗多粘菌素耐药鲍曼不动杆菌
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01268-16. Print 2017 Mar.
引用本文的文献
1
Sulbactam for carbapenem-resistant infections: a literature review.舒巴坦用于耐碳青霉烯类感染：一项文献综述。
JAC Antimicrob Resist. 2025 Apr 12;7(2):dlaf055. doi: 10.1093/jacamr/dlaf055. eCollection 2025 Apr.
2
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.耐碳青霉烯鲍曼不动杆菌感染的治疗方法
Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6. Epub 2024 Nov 28.
3
Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Infections-A Meta-Analysis.多耐药感染患者中基于头孢哌酮/舒巴坦与非头孢哌酮/舒巴坦治疗方案的疗效比较——一项荟萃分析
Antibiotics (Basel). 2024 Sep 23;13(9):907. doi: 10.3390/antibiotics13090907.
4
Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients.COVID-19 患者中碳青霉烯类耐药鲍曼不动杆菌的三种药物联合治疗的早期启动。
J Antimicrob Chemother. 2023 Apr 3;78(4):1034-1040. doi: 10.1093/jac/dkad042.
5
Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an Pharmacodynamic Model.在药效学模型中，米诺环素单独及与多粘菌素B、美罗培南和舒巴坦联合应用对碳青霉烯类敏感及耐药鲍曼不动杆菌的作用
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01680-20.
6
Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.在体外膜肺氧合支持期间，对患有危及生命的严重感染的重症患者进行亚胺培南的药代动力学和蒙特卡洛给药模拟。
Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):735-747. doi: 10.1007/s13318-020-00643-3.
7
Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.儿童耐碳青霉烯类革兰氏阴性菌感染。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.02183-19.
8
Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.治疗重症患者耐多药鲍曼不动杆菌肺炎的抗菌药物：系统评价和贝叶斯网状meta 分析。
Crit Care. 2017 Dec 20;21(1):319. doi: 10.1186/s13054-017-1916-6.
9
Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.预测不可预测之事：抗菌药物管理与不动杆菌感染综述
Infect Dis Ther. 2017 Jun;6(2):149-172. doi: 10.1007/s40121-017-0149-y. Epub 2017 Mar 4.
10
Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.群体药代动力学和药效学建模以优化鲍曼不动杆菌引起的严重脓毒症重症患者的舒巴坦给药方案
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7236-7244. doi: 10.1128/AAC.01669-16. Print 2016 Dec.
本文引用的文献
1
Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.重症监护病房呼吸机相关性革兰氏阴性杆菌肺炎患者中多利培南的药效学。
Int J Antimicrob Agents. 2012 Nov;40(5):434-9. doi: 10.1016/j.ijantimicag.2012.07.014. Epub 2012 Sep 7.
2
Stability of beta-lactamase inhibitors and beta-lactam antibiotics in parenteral dosage forms and in body fluids and tissue homogenates: a comparative study of sulbactam, clavulanic acid, ampicillin and amoxycillin.β-内酰胺酶抑制剂和β-内酰胺类抗生素在注射剂型和体液及组织匀浆中的稳定性：舒巴坦、克拉维酸、氨苄西林和阿莫西林的比较研究。
Int J Antimicrob Agents. 1996 Apr;6 Suppl:S31-4.
3
Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.大剂量氨苄西林/舒巴坦与多粘菌素单药治疗多重耐药鲍曼不动杆菌呼吸机相关性肺炎的疗效及安全性比较
J Infect. 2008 Jun;56(6):432-6. doi: 10.1016/j.jinf.2008.04.002. Epub 2008 May 23.
4
High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii.大剂量氨苄西林-舒巴坦作为耐多药鲍曼不动杆菌所致晚发性呼吸机相关性肺炎的替代治疗方法。
Scand J Infect Dis. 2007;39(1):38-43. doi: 10.1080/00365540600951184.
5
Prevention of resistance: a goal for dose selection for antimicrobial agents.预防耐药性：抗菌药物剂量选择的一个目标。
Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S42-50. doi: 10.1086/344653.
6
Completely resistant Acinetobacter baumannii strains.完全耐药的鲍曼不动杆菌菌株。
Infect Control Hosp Epidemiol. 2002 Aug;23(8):477-9. doi: 10.1086/502091.
7
Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.在台湾一所大学医院引发医院感染的泛耐药鲍曼不动杆菌
Emerg Infect Dis. 2002 Aug;8(8):827-32. doi: 10.3201/eid0805.020014.
8
Optimization in development of acetaminophen syrup formulation.对乙酰氨基酚糖浆制剂开发中的优化
Drug Dev Ind Pharm. 2002 Mar;28(3):345-51. doi: 10.1081/ddc-120002850.
9
Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains.舒巴坦对由敏感和中度敏感鲍曼不动杆菌菌株引起的实验模型的疗效。
J Antimicrob Chemother. 2001 Apr;47(4):479-82. doi: 10.1093/jac/47.4.479.
10
beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.舒巴坦及舒巴坦/头孢哌酮的β-内酰胺酶抑制作用和体外活性
Clin Infect Dis. 1997 Mar;24(3):494-7. doi: 10.1093/clinids/24.3.494.
Zotero 插件